Latest filing published 14 May 2024 for Akebia Therapeutics, Inc., €14k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -44.2%Entry US$19.56 · Close at T+365 US$10.92
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Nicole R. Hadas: trading record in brief
Nicole R. Hadas (senior executive) discloses dealings in Akebia Therapeutics, Inc. to SEC (Form 4). Between 25 March 2014 and 13 May 2024, the trades on record add up to 48 filings.
The open-market side counts 1 purchase for €43k alongside 31 sales for €582k. Netting one side against the other leaves €539k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 15 share grants. Since January 2024: no purchases and 3 sales on the market.
Most recently, on 14 May 2024, the filings show an open-market sale worth €14k in Akebia Therapeutics, Inc. The most recent open-market purchase was published on 27 March 2014, 4,610 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Nicole R. Hadas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 12,016 shares@ US$1.2625.4% of flowCommon StockSEC:0001562180-24-004026:0
- 5,974 shares@ US$1.5815.7% of flowCommon StockSEC:0001562180-24-002022:0
- 7,411 shares@ US$1.5218.8% of flowCommon StockSEC:0001562180-24-001995:0
- 149,300 shares0Common StockSEC:0001562180-24-000973:0
- 63,186 shares@ US$1.2212.2% of flowCommon StockSEC:0001562180-23-004504:1
- 200,000 shares0Common StockSEC:0001562180-23-004504:0
- 100,000 shares0Common StockSEC:0001562180-23-004169:0
- 6,613 shares@ US$0.87750.9% of flowCommon StockSEC:0001562180-23-002200:1
- 1,088 shares@ US$0.87750.2% of flowCommon StockSEC:0001562180-23-002200:2
- 5,333 shares@ US$0.87758.0% of flowCommon StockSEC:0001562180-23-002200:0
- 6,677 shares@ US$0.81329.3% of flowCommon StockSEC:0001562180-23-002037:0
- 6,873 shares@ US$2.172.3% of flowCommon StockSEC:0001562180-22-002161:2
- 6,556 shares@ US$2.172.2% of flowCommon StockSEC:0001562180-22-002161:3
- 1,078 shares@ US$2.170.4% of flowCommon StockSEC:0001562180-22-002161:4
- 50,000 shares0Common StockSEC:0001562180-22-002161:1
- 6,555 shares@ US$2.154822.8% of flowCommon StockSEC:0001562180-22-002161:0
- 1,060 shares@ US$3.400.6% of flowCommon StockSEC:0001562180-21-002542:0
- 10,192 shares0Common StockSEC:0001562180-21-002356:0
- 62,000 shares0Common StockSEC:0001562180-21-001785:0
- 6,309 shares@ US$3.403.7% of flowCommon StockSEC:0001562180-21-001785:1
- 7,976 shares@ US$3.404.6% of flowCommon StockSEC:0001562180-21-001785:2
- 7,050 shares@ US$8.7042.4% of flowCommon StockSEC:0001562180-20-001936:1
- 62,000 shares0Common StockSEC:0001562180-20-001936:0
- 11,929 shares@ US$7.7021.9% of flowCommon StockSEC:0000899243-19-010589:0
- 65,000 shares0Common StockSEC:0001562180-19-001676:0
25 of 46 declarations
